-- 週五,生質燃料原料期貨小幅上漲,跟隨原油價格上漲的步伐,原油價格的上漲提振了對生質柴油原料的需求,生質柴油被視為部分替代燃料。 芝加哥期貨交易所5月大豆期貨合約上漲0.06%,至每蒲式耳11.60美元。 5月豆油期貨合約上漲0.07%,至每磅71.66美分。 由於中東緊張局勢持續,原油價格居高不下,布蘭特原油價格達到每桶104.66美元,增加了對生物燃料替代品及其各種原料的需求。 供應方面,美國大豆的生長狀況看起來不錯,已完成12%的種植,遠高於五年平均。然而,市場正密切關注定於下個月舉行的中美貿易談判,根據Trading Economics預測,此次談判預計將成為提振需求的重要催化劑。 阿根廷是另一個主要供應國,該國的大豆作物正面臨天氣相關的延誤。同時,據ADMIS研究團隊稱,由於一小群卡車司機舉行抗議活動,該國奎肯港的18艘船被困。 在亞洲,受令吉走軟和原油價格上漲的支撐,馬來西亞棕櫚油期貨價格週五小幅走高。原油價格上漲使得生質柴油更具吸引力,此外,厄爾尼諾現象風險加劇以及生質柴油混合比例上升也推高了棕櫚油價格。 繼週四回落後,馬來西亞衍生性商品交易所5月原棕櫚油合約上漲0.27%,報每噸4,517令吉(1,139.22美元)。 6月合約也上漲0.29%,報每噸4,565令吉。 本週兩份合約均上漲近2%,扭轉了前兩週的跌勢。 儘管令吉走軟(過去一周下跌0.32%),且原油價格飆升(根據Trading Economics的數據顯示,布蘭特原油期貨價格觸及每桶105.98美元),但馬來西亞棕櫚油價格週五仍出現下跌。 馬來西亞棕櫚油理事會週五表示,預計短期內棕櫚油價格將維持在每噸4,500令吉以上,並指出厄爾尼諾現象可能對產量造成威脅。 該理事會也強調,馬來西亞正在推進生質柴油配方升級,從目前的B10轉向B15,預計每年可額外吸收100萬至150萬噸棕櫚油。 理事會表示,印尼和泰國也正在推行類似的生質柴油計劃,兩國都在提高生質柴油的配方比例,預計將進一步加劇短期內的市場供應緊張。 據價格報告機構MySteel稱,由於中東局勢短期內不太可能緩解,且原油價格再次飆升,棕櫚油作為生物柴油原料的作用日益凸顯,支撐了其價格。 在美國,儘管多個國家大力推廣乙醇摻混,且原油價格上漲,使其成為主要能源進口國的理想燃料來源,但紐約商品交易所(NYMEX)5月交割的乙醇期貨價格週五仍下跌0.50%,至每加侖1.98美元。 美國能源資訊署(EIA)發布的數據顯示,截至4月17日當週,美國乙醇日產量從前一周的110萬桶降至100萬桶。 根據美國能源資訊署 (EIA) 數據顯示,原油出口量從 81,000 桶/日增至 91,000 桶/日,而原油庫存從 2,670 萬桶增至 2,690 萬桶。
Related Articles
National Australia Bank Shares Down After Resolution of Union Court Proceedings
National Australia Bank (ASX:NAB) shares were down about 1% in recent Monday trade following a Friday settlement with the Finance Sector Union of Australia to resolve court proceedings related to excessive additional working hours for employees.The settlement, reached on a without-admissions basis through mediation, includes the establishment of a health, safety, and well-being framework to mitigate the risks linked to working additional hours, and calls for greater oversight of such risks.The union and the bank said in a joint statement that they are "committed to continuing to work together to ensure fair and sustainable outcomes for all [National Australia Bank] employees."
Clinuvel Pharmaceuticals Says FDA Removes Post-Authorization Requirement for Implant
Clinuvel Pharmaceuticals (ASX:CUV) said the US Food and Drug Administration (FDA) removed a requirement for a post-authorization phase one study on cardiac repolarization in relation to its Scenesse implant upon reviewing its long-term safety profile, according to a Monday filing with the Australian bourse.Scenesse is used to treat patients with erythropoietic protoporphyria, a disease that causes intolerance to light.The FDA concluded that the study was no longer needed since it would not yield valuable safety information, the filing said.
XRF Scientific Completes Acquisition of Combustion Gas Analysis Business
XRF Scientific (ASX:XRF) has completed the acquisition of the combustion gas analysis business from Bruker AXS, according to a Monday Australian bourse filing.The company entered a binding agreement to acquire the combustion gas analysis business for $4 million upfront plus a potential $1 million earnout based on 7% of net revenue over three years, an earlier filing showed.